A new arthritis pain medicine developed by a small Chapel Hill company is starting to get some major marketing.
The U.S. Food and Drug Administration approved Vimovo in late April. The drug was developed by researchers at Pozen, founded in 1996 by CEO John Plachetka, a former Glaxo executive.
Pozen's larger partner AstraZeneca, which is marketing Vimovo and will keep most of the drug's revenue, began promoting the drug in September.
That effort now includes advertising in print media, including a two-page ad in the News & Observer on Friday. AstraZeneca spokeswoman Sandra Heinig said she couldn't comment on specifics of the promotional efforts for competitive reasons but that the ads also are running in other newspapers.